Not Yet RecruitingPhase 2Phase 3ACTRN12626000236392

Effectiveness of topical timolol compared with oral propranolol for infant hemangiomas

Comparison of Topical Timolol with Oral Propranolol in Terms of Efficacy and Treatment Outcomes for Infantile Hemangiomas: A Randomized Controlled Trial.


Sponsor

King edward Medical University Lahore

Enrollment

40 participants

Start Date

Mar 18, 2026

Study Type

Interventional

Conditions

Summary

This study will help us by comparing the efficacy of topical timolol with oral propranolol in treating the infantile hemangiomas, as oral propranolol has been used traditionally for its treatment but it has more side effects and requires monitoring for hypotension and hypoglycemia. topical timolol is established as a much safer alternative. So we want to find if it is also comparable with regarding to its efficacy and outcomes. This study will provide valuable insights for healthcare providers, policymakers, and families, ultimately contributing to the development of patient-centred care


Eligibility

Sex: Both males and femalesMin Age: 1 MonthsMax Age: 12 Monthss

Inclusion Criteria3

  • o Infants aged 1 to 12 months.
  • o Diagnosed with superficial infantile hemangiomas with no complications requiring treatment.
  • o Parental consent obtained

Exclusion Criteria3

  • o Infants with deep hemangiomas.
  • o Infants with contraindications to beta-blockers (e.g., bradycardia, hypotension, asthma).
  • o Infants with significant comorbidities that could affect the study outcomes

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The pediatric population with simple superficial infantile hemangioma will be treated in two groups. One group will be treated with topical timolol applied thrice a day, Group A: Topical timolol (0.5

The pediatric population with simple superficial infantile hemangioma will be treated in two groups. One group will be treated with topical timolol applied thrice a day, Group A: Topical timolol (0.5% eye drops) 1 drop per cm2 applied topically 3 thrice a day to the hemangioma for 4 months. Monthly follow ups will be done for first 4 months to evaluate the response of the treatment in both groups. Contact details of individuals will be obtained after consent for adherence to the follow ups.


Locations(1)

Punjab, Pakistan

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12626000236392